Nav1.5 Ser571 Phosphorylation Links Aging to Cardiac Dysfunction

Study Background and Research Question

Aging is the principal independent risk factor for chronic heart failure and related cardiac complications. As the population of individuals over 65 years continues to grow, understanding the cellular and molecular substrates of age-associated cardiac dysfunction is a critical research priority. One well-documented hallmark of the aging myocardium is impaired ventricular relaxation, commonly termed diastolic dysfunction, which is often accompanied by prolonged ventricular repolarization. Recent evidence suggests that the late sodium current (INa,L), a sustained inward Na⁺ current resulting from incomplete inactivation of sodium channels, becomes pathologically augmented in aged cardiomyocytes. However, the molecular events linking INa,L dysregulation to the functional decline of the aging heart remain incompletely understood. The reference study (Am J Physiol Heart Circ Physiol 326: H1424–H1445, 2024) addresses whether specific post-translational modifications of the cardiac sodium channel Nav1.5—especially phosphorylation at Serine 571 (Ser571)—directly drive the maladaptive increase in INa,L and, consequently, the electromechanical manifestations of aging myopathy.

Key Innovation from the Reference Study

The central innovation of this research lies in its mechanistic dissection of how Nav1.5 phosphorylation at Ser571 modulates late sodium current and links this molecular event to age-related cardiac dysfunction. The study leverages genetically engineered mouse models with targeted mutations at Ser571 to either mimic persistent phosphorylation (phosphomimetic, gain-of-function) or prevent phosphorylation (phosphoablated, loss-of-function). This approach allows the authors to causally connect changes in INa,L with the emergence of delayed repolarization, diastolic impairment, and arrhythmogenic potential in the aging heart—bridging a longstanding gap in the pathophysiological understanding of cardiac aging.

Methods and Experimental Design Insights

The investigators employed a range of in vivo and in vitro cardiac electrophysiology techniques to interrogate the role of Nav1.5 Ser571 phosphorylation in aging. Key design elements include:

• Use of wild-type C57Bl/6 mice at various ages (adult: ~3–5 months; aged: ~18–30 months) to establish baseline aging phenotypes.
• Generation of two genetically modified mouse lines: one harboring a phosphomimetic Ser571 mutation (to enhance INa,L) and another with a phosphoablated mutation (to stabilize/reduce INa,L).
• Electrocardiogram (ECG) analysis for QT interval measurement, and echocardiography for diastolic function assessment.
• Patch-clamp recordings and Ca²⁺ transient analyses in isolated ventricular myocytes to quantify INa,L, action potential duration (APD), and myocyte contractile properties.
• Comparative analyses across genotypes and age groups to isolate the contribution of Ser571 phosphorylation to age-related phenotypes.

This multifaceted design enables rigorous attribution of observed electrophysiological and mechanical changes to specific molecular modifications of the sodium channel.

Core Findings and Why They Matter

The study's key findings reveal a direct mechanistic link between Nav1.5 Ser571 phosphorylation, enhanced late sodium current, and the functional deterioration of the aging heart:

• INa,L is augmented in aged cardiomyocytes: Compared to adult mice, ventricular myocytes from aged animals exhibit a ~60% increase in late sodium current and a ~50% prolongation in action potential duration at 90% repolarization.
• QT prolongation and diastolic dysfunction emerge with aging: Wild-type mice at 18 months develop both protracted QT intervals and impaired diastolic filling—clinical surrogates of electrical and mechanical dysfunction in the aged heart.
• Phosphomimetic Ser571 mutation recapitulates aging phenotypes prematurely: Mice engineered to mimic persistent phosphorylation at Ser571 (gain-of-function) display prolonged repolarization and impaired diastolic function as early as 5 months of age, supporting a causal role for Ser571-mediated INa,L enhancement.
• Phosphoablated Ser571 mutation protects against age-related decline: Mice with a loss-of-function mutation at Ser571 are largely resistant to age-associated QT prolongation and diastolic dysfunction, underscoring the specificity of this phosphorylation site in regulating pathological INa,L.
• Myocyte contractile and Ca²⁺ cycling defects mirror INa,L changes: Delayed Ca²⁺ transient decay and slowed myocyte shortening/relengthening kinetics in aged wild-type and phosphomimetic mutant myocytes highlight the downstream impact of INa,L dysregulation on excitation-contraction coupling.
• INa,L inhibition reverses aging phenotypes: Pharmacological suppression of late sodium current restores normal repolarization and diastolic function in aged wild-type mice, affirming the translational relevance of targeting INa,L in age-related cardiac dysfunction.

These results collectively demonstrate that Nav1.5 Ser571 phosphorylation and the resultant late sodium current are central drivers of the electromechanical impairments observed in the aging myocardium, with direct implications for arrhythmia prevention research and cardiac aging models.

Comparison with Existing Internal Articles

Recent internal resources provide complementary perspectives on the mechanistic and translational significance of late sodium current modulation in cardiac research. For example, the article "Nav1.5 Ser571 Phosphorylation Drives Age-Related Cardiac Dysfunction" summarizes the molecular logic by which Ser571 phosphorylation enhances INa,L, reinforcing the causality established in the reference study. Further, several practical guides—such as "GS967: Advanced Cardiac Late Sodium Current Inhibitor in Research" and "GS967: Cardiac Late Sodium Current Inhibitor for Aging Models"—detail how selective inhibitors like GS967 can be leveraged in in vitro cardiac electrophysiology and arrhythmia prevention research to experimentally isolate INa,L mechanisms. These resources underline the convergence of mechanistic insight and experimental capability in advancing cardiac aging studies.

Limitations and Transferability

While the use of genetically engineered mouse models provides strong causal evidence for the role of Nav1.5 Ser571 phosphorylation in regulating late sodium current and cardiac aging phenotypes, some limitations should be recognized:

• Species specificity: Mouse models may not fully recapitulate the complexity of human cardiac aging, especially regarding arrhythmogenicity and diastolic dysfunction.
• Pharmacological translation: The pharmacodynamics and selectivity of INa,L inhibitors in murine versus human tissue warrant careful consideration before extrapolating to clinical applications.
• Complexity of aging: Multiple molecular pathways contribute to the aged cardiac phenotype; while Ser571 phosphorylation is necessary and sufficient in this model, it may be only one component of a broader network in human disease.

Nonetheless, the demonstration that INa,L inhibition can reverse core features of aging myopathy in vivo provides a robust proof-of-principle for translational studies and the development of targeted interventions.

Protocol Parameters

• Model selection: For studies of age-related cardiac dysfunction, use wild-type and genetically modified mice (gain- or loss-of-function at Nav1.5 Ser571), ideally at both adult and aged time points (e.g., 3–5 months vs. 18–30 months).
• INa,L quantification: Employ whole-cell patch-clamp techniques in isolated ventricular myocytes to directly measure late sodium current amplitude and action potential duration.
• Pharmacological inhibition: When evaluating the impact of late sodium current inhibition, apply a selective inhibitor such as GS967 at concentrations validated for INa,L selectivity (e.g., 0.13 μM in ventricular myocytes, as reported in product information).
• Functional assessment: Use echocardiography for diastolic function and ECG for QT interval analysis; combine with Ca²⁺ imaging and myocyte contractility assays for mechanistic studies.
• Workflow integration: Incorporate inhibitor pretreatment in both acute and chronic protocols to differentiate immediate versus adaptive effects on cardiac electrophysiology.

Research Support Resources

Researchers seeking to replicate or extend these findings in arrhythmia prevention research or in vitro cardiac electrophysiology will benefit from highly selective cardiac late sodium current inhibitors. GS967 (SKU B5850) is a potent tool compound, exhibiting an IC₅₀ of 0.13 μM in ventricular myocytes and well-documented selectivity for late INa over peak current, as described in its product dossier. For practical protocol integration, recent workflow articles such as "GS967: Advanced Cardiac Late Sodium Current Inhibitor in Research" and "GS967: Cardiac Late Sodium Current Inhibitor for Aging Models" provide detailed guidance on compound handling, dosing, and experimental design in translational cardiac studies. APExBIO offers GS967 for research use, supporting experimental efforts to delineate the mechanisms of cardiac aging and arrhythmia.